Clinical Trials Sponsored by Horizon Pharma, Inc.

Total 2547 results

Horizon Pharma USA, Inc.

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Cystinosis

United States, Brazil
Horizon Pharma USA, Inc.

Completed

A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

Aldehyde Dehydrogenase-2 (ALDH2) Deficiency

United States
Horizon Therapeutics USA, Inc.

Completed

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

Thyroid Eye Disease | Chronic (Inactive) Thyroid Eye Disease

United States
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC)

Thyroid Eye Disease | Graves' Orbitopathy

United States, Italy, Germany
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X)

Thyroid Eye Disease

Italy, United States, Germany
Horizon Pharma USA, Inc.

Approved for marketing

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (EAP)

Thyroid Eye Disease | Graves' Orbitopathy

United States
Horizon Pharma USA, Inc.

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Cystinosis

France, United States, United Kingdom, Belgium, Italy, Netherlands
Horizon Pharma USA, Inc.

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Terminated

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Mitochondrial Diseases

United States
Horizon Pharma USA, Inc.

Completed

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.

Completed

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Cystinosis

United States
Horizon Pharma USA, Inc.

Completed

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Thyroid-Associated Ophthalmopathy | Thyroid Associated Ophthalmopathies

United Kingdom, United States, Germany, Italy
Horizon Pharma USA, Inc.

Completed

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Cystic Fibrosis (CF)

Germany, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.

Completed

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (MITO-001)

Inherited Mitochondrial Disease, Including Leigh Syndrome

United States
Horizon Therapeutics USA, Inc.

Completed

A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease

Thyroid Eye Disease

United States
Horizon Therapeutics USA, Inc.

Terminated

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis

United States
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Israel, New Zealand, Canada
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (TIS)

Cystic Fibrosis

United States, Ireland, United Kingdom, France, Germany, Israel
Horizon Pharma Ireland, Ltd., Dublin Ireland
Ucyclyd Pharma, Inc.

Completed

A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group

Hepatic Encephalopathy | Urea Cycle Disorders

Ukraine
Horizon Pharma Ireland, Ltd., Dublin Ireland
Ucyclyd Pharma, Inc.

Completed

A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)

Healthy

Ukraine
University of Pittsburgh
Horizon Pharma USA, Inc.

Recruiting

Exome and Genome Analysis to Elucidate Genetic Etiologies and Population Characteristics in the Plain Community

Undiagnosed Disease

United States
Horizon Pharma Rheumatology LLC

Completed

Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout (EyesOnGOUT)

Refractory Chronic Gout

United States
Horizon Therapeutics, LLC

Terminated

Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs) (THRIVE)

Urea Cycle Disorder

United States
Horizon Therapeutics, LLC

Completed

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Urea Cycle Disorder

United States, Canada
Horizon Therapeutics, LLC

Completed

Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)

Urea Cycle Disorder

United States, Spain, Italy, Switzerland
Horizon Therapeutics, LLC

Completed

To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

Urea Cycle Disorders

United States, Canada
Horizon Therapeutics Ireland DAC

Completed

Study to Evaluate HZN-457 in Healthy Volunteers

Healthy

New Zealand
Horizon Therapeutics Ireland DAC

Completed

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout (MIRROR RCT)

Gout

United States
Horizon Therapeutics Ireland DAC

Completed

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

Uncontrolled Gout | Kidney Transplant

United States
Horizon Therapeutics Ireland DAC

Completed

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout (MIRROR OL)

Gout

United States
Horizon Therapeutics Ireland DAC

Completed

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Uncontrolled Gout

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis (SUNRAY)

Rheumatoid Arthritis
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders

Urea Cycle Disorders

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy (HALT-HE)

Hepatic Encephalopathy | Cirrhosis

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment

Osteoarthritis | Rheumatoid Arthritis | Chronic Low Back Pain | Chronic Regional Pain Syndrome | Chronic Soft Tissue Pain

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers

Peptic Ulcer
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)

Urea Cycle Disorders

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Drug Toxicity

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Terminated

Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

Hepatic Encephalopathy

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

Ulcer
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma (MONA)

Asthma

France
Orion Corporation, Orion Pharma

Completed

Safety and Pharmacokinetics of ODM-209 (STESIDES)

Advanced Breast Cancer | Metastatic Breast Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Finland, France, Denmark
Orion Corporation, Orion Pharma

Completed

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (EASYRELIEF)

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler (TEMPO)

Healthy Volunteers

Finland

3

Subscribe